Navigation Links
Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products
Date:5/12/2008

oducts International, formerly Glycobiotics International Inc., asserting that the company infringed on certain Mannatech Ambrotose patents originally issued in 2005 and 2007.

"A company's ability to stop patent infringement requires not only the issuance of a patent, but also a favorable court interpretation of the patent and a defense of its validity," said Keith Clark, general counsel at Mannatech. "This decision, coupled with the company's successful outcomes in the Markman hearing rulings last year, paves the way for protecting these critical Mannatech technology patents moving forward."

The verdict was delivered on Friday, May 9, 2008, in the U.S. District Court for the Northern District of Texas, Dallas Division. Jurors reached their decision following five days of testimony before Federal Magistrate Jeff Kaplan.

Mannatech was represented by Lynn Tillotson & Pinker, LLP attorneys Eric W. Pinker, P.C., Mark E. Turk, Renee S. Strickland and Britta Erin Stanton as well as Chalker Flores, LLP attorneys Edwin Flores, Daniel J. Chalker and Scott A. Meyer.

About Mannatech

Mannatech, Incorporated, is a global wellness solutions provider of innovative, high-quality, proprietary nutritional supplements, topical and skin care products, and weight management products sold through independent associates and members located in the United States and the international markets of Canada, Australia, the United Kingdom, Japan, New Zealand, the Republic of Korea, Taiwan, Denmark, Germany, and South Africa.

Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Simil
'/>"/>

SOURCE Mannatech, Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Study validates Pittsburgh Compound-B in identifying Alzheimers disease brain toxins
2. NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures
3. Mannatech Launches Business in South Africa
4. Sports Illustrated Names Team Mannatech Athlete to Top 25 Tough List
5. Mannatech Goes Green and Supports Local Earth Day Celebrations
6. Mannatech to Begin Selling Nutritional Supplements in South Africa
7. Mannatech Names New VP of Regulatory Affairs, Quality Assurance
8. Mannatech to Open Centralized-Management Office in Switzerland
9. Mannatech Hosts Australasian Convention
10. Mannatech Hosts Japan National Convention
11. Mannatech Launches Phase One of New Sales and Training Tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...K, Nov. 21 The general membership ...induct three new individuals at their Annual,Awar...re hotel in New York. A,Lifetime Achievement Awar...into the Medical Advertising Hall of Fame are: , ...r with an account position,at Sudler & Hennes...
(Date:11/21/2008)...ound 2 popular drugs do not cause genetic damage t... 21 (HealthDay News) -- Two popular medications fo...r (ADHD) do not cause genetic damage linked to an ...says. , The study, done by researchers at Duke ...tes of Health, counters a previous one that report...
(Date:11/21/2008)... Nov. 21 In a statewide survey, 33...Institute for Surgery at Presbyterian Hospital of ... annual listing of " Super Doctors ." , , E...ith Key Professional Media, Inc. to survey more th...f Texas to ask, "If you needed medical care, which...
(Date:11/21/2008)... Ind., Nov. 21 Symmetry ... provider of products to the global orthopedic dev...today that Brian S. Moore, President and Chief Exe...ident and Chief Financial Officer, are scheduled t...Care Conference at The New York Palace Hotel on We...
Breaking Medicine News(10 mins):Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2
...he Food and Drug Administration cracked down on In...d lip balm, declaring them illegal and ordering th...ops in particular pose a risk to children because ...e quantity of nicotine could be potentially danger...
...ccording to a research, women who live at high alt...heir conclusions after finding lower concentration... health and youthfulness, in women living in the m...ers looked at a control group of 160 women of simi...
...ccording to a new study taking cholesterol-lowerin... of peripheral neuropathy. Previous research has s...lesterol levels. However, researchers in Texas now...k of peripheral neuropathy, a condition marked by ...
...ccording to a new review of the medical proof, the... of venous leg ulcers. Venous leg ulcers are cause...ong people aged 60 or over. Standard treatment is ...p to a third of people still have unhealed ulcers ...
Other Medicine News:Health News:High Altitude ‘Speeds up ageing process 2
(Date:11/19/2008)... report basic findings on critical enzyme,s regula...reat an array of disorders , , MEMPHIS, Ten... at St. Jude Children,s Research Hospital have gai...y,s enzyme workhorses called calpains. , , ...unction in many cellular processes, including the ...
(Date:11/19/2008)...19 Isogen, a contract development ...g, today announced the first,phase launch of its ...to,specifically address the process, facility and...2 billion highly-niched, low-volume clinical and,...ent. , Companies can invest over $100 milli...
(Date:11/18/2008)... NeuroDiscovery Ltd (ASX... and drug development Company,and Sosei Group Co...ading,international biopharmaceutical company, to...rther pivotal pre-clinical efficacy data for NSL-0...l therapy for neuropathic pain and has,successful...
(Date:11/18/2008)...18 Arlington Medical Resources (AM... the pharmaceutical and diagnostic,imaging indust... Privigen was,sold in the U.S. during the third q...ntravenous immune globulin (IVIG) and was launched...created from the blood plasma of thousands,of don...
Breaking Medicine Technology:New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Isogen Launches Major New Facility to Address Global Biopharma Demand 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 250 Million Pound Challenge Teams Up With Churches to Spread the Gospel of Healthy Living 10345 150 Million Pound Challenge Teams Up With Churches to Spread the Gospel of Healthy Living 10345 250 Million Pound Challenge Teams Up With Churches to Spread the Gospel of Healthy Living 10345 350 Million Pound Challenge Teams Up With Churches to Spread the Gospel of Healthy Living 10345 4SoluLinK Introduces ChromaLink 28TM 29 Biotin Labeling Kit to Biotinylate and Measure With One Reagent 2822 1SoluLinK Introduces ChromaLink 28TM 29 Biotin Labeling Kit to Biotinylate and Measure With One Reagent 2822 2Prison study to investigate link between diet and behavior 2042 1Prison study to investigate link between diet and behavior 2042 2Carbon monoxide may cause long lasting heart damage 2038 1Carbon monoxide may cause long lasting heart damage 2038 2
...mboEmbolism (VTE) is Reduced by a,Significant 43% ...xane(R) / Lovenox(R), BRIDGEWATER, N.J., April 20,...ounced the publication of the PREVAIL (Prevention,...parin) trial in,the April 21st issue of The Lancet...administration of Clexane(R) / Lovenox(R),(enoxapa...
... 23, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB...ectious disease and dermatology, today announced t...ompany,s antimicrobial,compounds: CSA-8 and CSA-13...rnal of Antimicrobial Agents and Chemotherapy, a,p...ety of,Microbiology, dedicated to advances in the ...
Other Medicine Technology:The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 2The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 3The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 4The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 5The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 6Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 2Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 3Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 4
The LH 755 simplifies and automates high-volume hematology testing by integrating expert automation and advanced technologies into one workcell. It delivers reliable, accurate results every time. Plu
Kinetic and endpoint methods for the quantitative determination of creatinine in serum.
For the quantitative determination of creatine kinase-MB in serum. Kinetic Reaction measured at 340 nm. Linearity: 700 IU/L at 37C.
Intended for the quantitative determination of magnesium in serum. Wavelength: 340 nm. Linearity: 9.7 mg/dL (4 mmol/L). Two vials, dry powder reagents.
Medicine Products: